Impfung von erwachsenen Patienten mit chronischen Lungenerkrankungen [Vaccination in adult patients with chronic lung diseases]
Details
Serval ID
serval:BIB_E4CB35851F55
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Impfung von erwachsenen Patienten mit chronischen Lungenerkrankungen [Vaccination in adult patients with chronic lung diseases]
Journal
Praxis
ISSN
1661-8157 (Print)
ISSN-L
1661-8157
Publication state
Published
Issued date
12/2024
Peer-reviewed
Oui
Volume
113
Number
11-12
Pages
297-305
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Abstract
In Switzerland, additional vaccinations against influenza, COVID-19, Streptococcus pneumoniae and varicella zoster virus (VZV), are recommended for patients with chronic lung diseases such as COPD, asthma or interstitial lung disease, since infectious diseases often lead to exacerbation of lung diseases resulting in increased disease burden and mortality. In this review we give an overview on recommended vaccinations for patients with chronic lung diseases, also including vaccinations against pertussis and RSV, which are recommended in international guidelines. While continuous development of vaccines against S. pneumoniae has given rise to high-valency vaccines covering up to 68% of S. pneumoniae variants in individuals aged ≥65 years, vaccination rates in this age group remain low in Switzerland (10% in 2020). Vaccination rates are higher for influenza, and particularly high-dose vaccines account for high vaccination efficacy in years of low strain matching in individuals at risk. Although mortality of COVID-19 decreased since the emergence of the first SARS-CoV-2 variant, patients with chronic lung disease are still at increased risk for exacerbation, unless vaccinated with variant-adjusted vaccines. VZV and Bordetella pertussis vaccination has also significantly countered reactivation and infection rates, respectively, and subunit vaccines against VZV show long duration. However, pertussis vaccination is still limited by its fast waning. A glimpse into the future presumes the introduction of new higher-valence vaccinations against S. pneumoniae, and several types of RSV vaccines are expected to enter the Swiss market soon.
Keywords
Humans, COVID-19/prevention & control, Switzerland, Aged, COVID-19 Vaccines/administration & dosage, Chronic Disease, Influenza Vaccines/administration & dosage, Pneumococcal Vaccines/administration & dosage, Adult, Vaccination, Lung Diseases, SARS-CoV-2/immunology, Pulmonary Disease, Chronic Obstructive, Vaccine efficacy, chronic lung diseases, exacerbation prevention, viral infections
Pubmed
Create date
08/01/2025 15:54
Last modification date
09/01/2025 7:05